Advertisement
U.S. markets open in 1 hour 47 minutes
Advertisement

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
1.1200-0.0200 (-1.75%)
At close: 04:00PM EST
1.1400 +0.02 (+1.79%)
Pre-Market: 06:12AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Performance Outlook
Previous Close1.1400
Open1.1500
Bid1.0400 x 3100
Ask1.1500 x 1800
Day's Range1.1000 - 1.1600
52 Week Range1.0250 - 3.3350
Volume707,209
Avg. Volume608,247
Market Cap185.931M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-0.4300
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.32
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ATAI Life Sciences N.V.
    Daily – Vickers Top Buyers & Sellers for 03/31/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • GlobeNewswire

    atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

    Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two nove

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Trulieve is challenging 280E cannabis taxation, seeking $143 million federal tax refund. TerrAscend raised its full year 2023 guidance, triggering a surge in stock price. Red White & Bloom won the race to acquire Aleafia Health after an earlier stumble. Key Takeaways; Psychedelic Sector Atai strengthened investment in IntelGenx technologies. Awakn’s […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.

  • CNW Group

    ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT

    This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023.